文献速递免疫规划传染病防控与疫情报告

异基因造血干细胞移植后肺炎球菌疫苗的长期免疫原性

Long-term pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation.
PubMed 文献 · Vaccine · 2018-11-27

该研究纳入移植后1年开始接种肺炎球菌疫苗的异基因造血干细胞移植受者,检测抗体应答并系统综述,发现PCV13应答率85%、PPSV23独特血清型62%,六项研究中保护率64%至98%,早期与晚期接种应答相似但晚期接种抗体维持更好,据此提出兼顾早晚期优势的接种方案。

要点

  • 移植后1年接种肺炎球菌疫苗,PCV13应答率85%,PPSV23独特血清型62%。
  • 系统综述六项研究保护率64%至98%,早期与晚期接种抗体应答相似。
  • 晚期接种后充足抗体应答维持更好,新方案兼顾早晚期优势。

核心结论

  • 异基因造血干细胞移植后肺炎球菌疫苗接种在晚期接种时抗体维持更佳,新方案兼顾早晚期接种优势。

研究设计与样本

  • 纳入移植后1年开始接种肺炎球菌疫苗的异基因造血干细胞移植受者,检测抗体应答并开展系统综述。
  • 103例患者中42例(41%)检测了抗体浓度。

主要发现

  • PCV13应答率85%,PPSV23独特血清型应答率62%。
  • 六项相关研究中保护率介于64%至98%。
  • 早期与晚期接种方案抗体应答相似,但晚期接种后充足抗体应答维持更好。

关键数值与推荐

  • 国际共识建议移植后3至6个月开始接种,荷兰方案为移植后12个月开始。
  • 新接种方案自2018年3月起在阿姆斯特丹两家学术医院引入。

临床怎么用

  • 移植后肺炎球菌疫苗接种可考虑兼顾早期与晚期接种优势的方案。
  • 即使充分复种,仍需警惕侵袭性肺炎球菌病(IPD)发生。

局限性

  • 仅41%患者检测了抗体浓度。
  • 长期免疫原性此前未被充分表征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infection with Streptococcus pneumoniae is a life-threatening, but vaccine preventable complication in patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). The international consensus on post allo-HSCT immunization schedules, starting 3-6 months after HSCT, focuses on short-term immunogenicity while long-term immunogenicity is not well characterized. The current Dutch immunization schedule, which starts at 12 months post allo-HSCT, was developed as a result of concerns on the coverage of long-term immunogenicity in international guidelines. We recently encountered two cases of allo-HSCT recipients who developed invasive pneumococcal disease (IPD) despite adequate revaccinations, which led us to question the immunogenicity of pneumococcal vaccinations in this patient group, and whether the currently existing vaccination schedules are appropriate. We included allo-HSCT recipients, vaccinated from one year after transplantation, and tested antibody responses to pneumococcal vaccination. We also performed a systematic review. Antibody concentrations were measured in 42 of 103 (41%) patients, with a response rate of 85% to PCV13 and 62% to PPSV23-unique serotypes. In six relevant studies, protection rates varied between 64 and 98%. Antibody responses in early and late vaccination schedules were similar, but adequate antibody responses were maintained better after late vaccination. Therefore, we propose a vaccination schedule that combines the advantages of early and late vaccination. This new schedule has been introduced since March 2018 in the two academic hospitals in Amsterdam, The Netherlands.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Langedijk AC, van Aalst M, Meek B, et al. Long-term pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation. Vaccine. 2018. PMID: 30502071. doi:10.1016/j.vaccine.2018.11.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。